These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 22099584

  • 1. Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG.
    Liu H, Zhang T, Chen R, McConkey DJ, Ward JF, Curley SA.
    J Surg Res; 2012 Jul; 176(1):147-53. PubMed ID: 22099584
    [Abstract] [Full Text] [Related]

  • 2. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N, Calipel A, Mouriaux F, Faussat AM, Mascarelli F.
    Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
    [Abstract] [Full Text] [Related]

  • 3. HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells.
    Ko JC, Chen HJ, Huang YC, Tseng SC, Weng SH, Wo TY, Huang YJ, Chiu HC, Tsai MS, Chiou RY, Lin YW.
    Regul Toxicol Pharmacol; 2012 Dec; 64(3):415-24. PubMed ID: 23069143
    [Abstract] [Full Text] [Related]

  • 4. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.
    Kurashina R, Ohyashiki JH, Kobayashi C, Hamamura R, Zhang Y, Hirano T, Ohyashiki K.
    Cancer Lett; 2009 Oct 18; 284(1):62-70. PubMed ID: 19464103
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of thymidine phosphorylase expression by using an HSP90 inhibitor potentiates the cytotoxic effect of cisplatin in non-small-cell lung cancer cells.
    Weng SH, Tseng SC, Huang YC, Chen HJ, Lin YW.
    Biochem Pharmacol; 2012 Jul 01; 84(1):126-36. PubMed ID: 22480737
    [Abstract] [Full Text] [Related]

  • 6. Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism.
    McCollum AK, Teneyck CJ, Sauer BM, Toft DO, Erlichman C.
    Cancer Res; 2006 Nov 15; 66(22):10967-75. PubMed ID: 17108135
    [Abstract] [Full Text] [Related]

  • 7. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition.
    Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, Ross D.
    Cancer Res; 2005 Nov 01; 65(21):10006-15. PubMed ID: 16267026
    [Abstract] [Full Text] [Related]

  • 8. 17-Allylamino-17-demethoxygeldanamycin and ritonavir inhibit renal cancer growth by inhibiting the expression of heat shock factor-1.
    Sato A, Asano T, Ito K, Asano T.
    Int J Oncol; 2012 Jul 01; 41(1):46-52. PubMed ID: 22470109
    [Abstract] [Full Text] [Related]

  • 9. Effects of Hsp90 inhibition in neuroblastoma: analysis of drug sensitivity, target modulation and the influence of bone marrow microenvironment.
    Jayanthan A, Fowler J, Hawkins L, Lamers F, Teja B, Incoronato A, Anderson R, Narendran A.
    J Exp Ther Oncol; 2008 Jul 01; 7(3):183-93. PubMed ID: 19066127
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
    Georgakis GV, Li Y, Rassidakis GZ, Martinez-Valdez H, Medeiros LJ, Younes A.
    Clin Cancer Res; 2006 Jan 15; 12(2):584-90. PubMed ID: 16428504
    [Abstract] [Full Text] [Related]

  • 11. Immune expression and inhibition of heat shock protein 90 in uveal melanoma.
    Faingold D, Marshall JC, Antecka E, Di Cesare S, Odashiro AN, Bakalian S, Fernandes BF, Burnier MN.
    Clin Cancer Res; 2008 Feb 01; 14(3):847-55. PubMed ID: 18245548
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
    Banerji U, Walton M, Raynaud F, Grimshaw R, Kelland L, Valenti M, Judson I, Workman P.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 1):7023-32. PubMed ID: 16203796
    [Abstract] [Full Text] [Related]

  • 13. p53 independent radio-sensitization of human lymphoblastoid cell lines by Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
    Fujii Y, Kato T, Kubota N, Fujimori A, Niwa O, Okayasu R.
    Oncol Rep; 2010 Jan 01; 23(1):199-203. PubMed ID: 19956882
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J, Pham NA, Cao MP, Hedley DW.
    Cancer Chemother Pharmacol; 2008 Apr 01; 61(4):669-81. PubMed ID: 17579866
    [Abstract] [Full Text] [Related]

  • 15. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.
    Al Shaer L, Walsby E, Gilkes A, Tonks A, Walsh V, Mills K, Burnett A, Rowntree C.
    Br J Haematol; 2008 May 01; 141(4):483-93. PubMed ID: 18373709
    [Abstract] [Full Text] [Related]

  • 16. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
    Francis LK, Alsayed Y, Leleu X, Jia X, Singha UK, Anderson J, Timm M, Ngo H, Lu G, Huston A, Ehrlich LA, Dimmock E, Lentzsch S, Hideshima T, Roodman GD, Anderson KC, Ghobrial IM.
    Clin Cancer Res; 2006 Nov 15; 12(22):6826-35. PubMed ID: 17121904
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.
    Sawai A, Chandarlapaty S, Greulich H, Gonen M, Ye Q, Arteaga CL, Sellers W, Rosen N, Solit DB.
    Cancer Res; 2008 Jan 15; 68(2):589-96. PubMed ID: 18199556
    [Abstract] [Full Text] [Related]

  • 18. Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells.
    Roforth MM, Tan C.
    Anticancer Drugs; 2008 Aug 15; 19(7):681-8. PubMed ID: 18594209
    [Abstract] [Full Text] [Related]

  • 19. Acquired resistance to HSP90 inhibitor 17-AAG and increased metastatic potential are associated with MUC1 expression in colon carcinoma cells.
    Liu X, Ban LL, Luo G, Li ZY, Li YF, Zhou YC, Wang XC, Jin CG, Ye JG, Ma DD, Xie Q, Huang YG.
    Anticancer Drugs; 2016 Jun 15; 27(5):417-26. PubMed ID: 26872308
    [Abstract] [Full Text] [Related]

  • 20. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
    Bonvini P, Gastaldi T, Falini B, Rosolen A.
    Cancer Res; 2002 Mar 01; 62(5):1559-66. PubMed ID: 11888936
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.